What was recalled
The U.S. Food and Drug Administration (FDA) has initiated a Class II recall involving specific lots of Multrys (Trace Elements Injection 4, USP), a sterile pharmaceutical product manufactured by American Regent, Inc. This is not a broad recall affecting every medication produced by the company, but rather a targeted action against specific batches that failed to meet strict quality control standards during the manufacturing or packaging process. The product in question is designed for intravenous infusion, meaning it is intended to be delivered directly into a patient’s bloodstream, which makes the purity of the solution critically important. American Regent, Inc., located in Shirley, New York, is the manufacturer responsible for these products, and the recall covers two distinct packaging configurations that are commonly used in hospital pharmacies and clinical settings.
The specific items subject to this recall are identified by their National Drug Codes (NDC), which serve as unique identifiers for pharmaceutical products in the United States. The first affected package is the 1 mL Single-Dose Vial, carrying the NDC number 0517-9302-01. The second configuration consists of a pack containing twenty-five 1 mL Single-Dose Vials, identified by the NDC number 0517-9302-25. Both of these package types are prescription-only (Rx Only) medications, indicating they are not available over-the-counter and require a healthcare provider’s authorization for distribution. The recall is specifically limited to Lot number 25163. It is important to note that while the expiration date for this lot is listed as April 30, 2027, the product is being pulled from circulation immediately due to safety concerns that arose prior to its intended use-by date.
This recall was officially announced and initiated on July 24, 2026. The affected products were distributed nationwide within the United States, meaning they could be present in medical facilities across all states, not just in New York where the manufacturer is headquartered. Because these trace element injections are often used in total parenteral nutrition (TPN) solutions to provide essential minerals and vitamins to patients who cannot eat or absorb nutrients through their digestive tract, the presence of any contamination poses a direct risk to vulnerable individuals. The scope of this recall is defined by the specific lot number and NDC codes provided above; if you are managing inventory for a healthcare facility or checking personal medical records, these identifiers are the only way to confirm whether your stock falls under this specific FDA action.
The hazard, explained
When the U.S. Food and Drug Administration issues a recall for a sterile injectable product like Multrys (Trace Elements Injection 4, USP), the concern is rarely about the medication’s chemical potency or its intended therapeutic effect. Instead, the danger lies in physical contamination. In this specific instance, American Regent, Inc. has identified that the solution contains foreign particulate matter. These are not microscopic impurities that dissolve or remain inert; they are distinct, tangible objects suspended in the fluid. The FDA report specifies that these particles have been identified as hair, glass, and/or paraformaldehyde. Understanding why this is critical requires looking at how intravenous (IV) delivery systems work and how the human body reacts to foreign solids entering the bloodstream directly.
Unlike taking a pill or receiving an injection into muscle tissue, where the material enters the body slowly and may be filtered or absorbed over time, IV infusion delivers substances directly into the venous system. This pathway bypasses several of the body’s natural filtration barriers, such as the digestive tract or the lymphatic system. When particulate matter is present in an IV bag or vial, those particles travel with the fluid and are deposited directly into the veins, eventually reaching the heart and then the lungs. The circulatory system is designed to handle liquids and dissolved gases, not solid debris. Consequently, even small amounts of foreign material can cause significant physical obstruction at the microscopic level.
The specific types of contaminants listed in this recall present different but equally serious risks. Glass shards, for example, are rigid and sharp. If injected intravenously, these fragments can physically damage the delicate endothelial lining of blood vessels. This trauma can lead to inflammation, clot formation (thrombosis), or embolism, where a piece of debris travels to smaller capillaries and blocks blood flow. Hair is another organic contaminant. While it may seem harmless, hair fibers can introduce biological material into a sterile environment, potentially triggering severe immune responses, granuloma formation (where the body walls off the foreign object with inflammatory cells), or serving as a nidus for bacterial growth if any microbes were also present. Paraformaldehyde is a chemical polymer that breaks down into formaldehyde. Formaldehyde is a known irritant and toxin; its presence in an injection can cause local tissue necrosis (death of cells) at the injection site or systemic toxicity if absorbed in sufficient quantities.
The severity of the harm depends on the size, number, and composition of the particles, as well as the volume of the infusion. A single large particle might lodge in a larger vessel, causing immediate blockage, while millions of microscopic particles can accumulate over time, leading to chronic inflammation or organ damage, particularly in the lungs (pulmonary capillary granulomas) and liver. Because the product is labeled "Rx Only" and intended for intravenous use, it is administered under medical supervision. However, if the contamination occurs during manufacturing or packaging—as suggested by the presence of hair and glass—the risk remains until the product is removed from the supply chain. This is why the FDA classified this as a Class II recall, indicating that use of the product could cause temporary or medically reversible serious injury, or pose a distant but serious threat to health.
Who is most at risk
To understand who is truly vulnerable in this situation, we first need to look at how this product is used. Multrys (Trace Elements Injection 4, USP) is not a medication you take at home like a pill or a syrup. It is a sterile injectable solution designed specifically for intravenous infusion. This means it goes directly into the bloodstream through an IV line. The product in question comes in very small volumes—either single-dose 1 mL vials or multi-packs of 25 such vials—and is labeled as prescription-only (Rx Only). Because of this, the people "at risk" are not random consumers walking into a pharmacy aisle. They are patients currently receiving hospital care, nursing home treatment, or specialized outpatient therapy who are being administered trace elements to maintain their nutritional balance.
The primary group at risk here is anyone who has received an infusion containing Lot #25163 of American Regent’s Multrys before the recall date of July 24, 2026. Since the distribution was nationwide, this includes patients in hospitals, clinics, and long-term care facilities across all U.S. states. However, the level of danger depends heavily on the patient’s own health status. When a sterile solution is contaminated with particulate matter—specifically hair, glass fragments, or paraformaldehyde—the risk is not just about ingesting something foreign; it is about that material entering the circulatory system directly.
Certain patients are more vulnerable to these complications than others. For instance, individuals with weakened immune systems, such as those undergoing chemotherapy, organ transplant recipients, or the elderly, are at higher risk because their bodies may struggle to fight off potential infections if the particulate matter introduces bacterial contaminants or triggers severe inflammatory responses. Additionally, patients with pre-existing conditions affecting blood vessels or heart function could be more susceptible to physical blockages or irritation caused by glass particles or other debris entering the vein. Even small amounts of paraformaldehyde, a chemical compound, can be toxic if introduced into the bloodstream in uncontrolled quantities, potentially causing systemic reactions that are harder for frail patients to withstand.
It is also important to note that because this is a trace element supplement, it is often given to patients who are critically ill or unable to eat normally. These individuals are already in a delicate physiological state. Adding the stress of a contaminated infusion can complicate their recovery or lead to acute adverse events. Therefore, while any patient receiving this specific lot is technically at risk, those with compromised health, advanced age, or critical care needs face the most serious potential consequences. If you or a loved one is in a hospital setting and has received IV fluids recently, it is wise to ask your care team if Multrys from Lot #25163 was used during treatment.
How to tell if you have the recalled item
If you are a patient who has recently received intravenous therapy, or if you are a healthcare professional managing inventory in a clinic, hospital, or long-term care facility, taking a moment to verify your supplies is a critical step in ensuring your safety. Because this recall involves a specific pharmaceutical product used for trace element supplementation, identifying the affected items requires careful attention to several distinct details on the packaging. The primary focus of this verification process is the drug name, the National Drug Code (NDC), the lot number, and the expiration date. By systematically checking these markers against the information provided by the Food and Drug Administration (FDA) and American Regent, Inc., you can determine with certainty whether your product is part of this Class II recall.
First, locate the vial itself. This recall specifically targets Multrys (Trace Elements Injection 4, USP), which is intended for intravenous infusion. It is essential to confirm that the bottle contains this exact formulation, as other trace element products may be safe. Next, examine the label closely for the National Drug Code (NDC), which serves as the unique identifier for the product. There are two specific NDCs involved in this recall: 0517-9302-01, which corresponds to a single 1 mL vial, and 0517-9302-25, which corresponds to a package containing 25 of these 1 mL vials. If your product bears either of these NDCs, it is a strong indicator that it may be included in the recall, but you must verify the lot number to be certain.
The most definitive way to confirm if your item is affected is to check the printed lot number and expiration date. The recall applies exclusively to Lot # 25163. If your vial or package displays this specific lot number, it must not be used. Additionally, verify the expiration date, which is listed as 4/30/2027. While a future expiration date might suggest freshness, in this context, it confirms that the product was manufactured and distributed under the conditions that led to the recall due to potential contamination with particulate matter, such as hair, glass, or paraformaldehyde. This product is prescription-only (Rx Only) and is distributed by American Regent, Inc., based in Shirley, New York.
If you are a patient and are unsure whether you have been administered this specific lot, do not panic, but do take action. Contact the healthcare provider who administered your infusion or the pharmacy that dispensed the medication. Provide them with the date of your visit and ask them to check their records for the NDC and lot number used during your treatment. If you are a medical professional conducting an inventory audit, physically inspect all stock of Multrys Trace Elements Injection 4, USP, looking specifically for the NDCs 0517-9302-01 or 0517-9302-25 and Lot # 25163. Quarantine any matching units immediately to prevent accidental administration. This careful verification process ensures that you are not exposed to the potential hazards associated with particulate contamination, allowing you to move forward with confidence and peace of mind.
What to do — step by step
If you or a healthcare provider currently have American Regent’s Multrys (Trace Elements Injection 4, USP) on hand, the most critical first action is to stop using it immediately. Because this specific recall addresses the presence of hazardous particulate matter—including hair, glass shards, and paraformaldehyde—administering the drug via intravenous infusion poses a direct and serious risk to patient safety. These contaminants can cause severe physical injury if they enter the bloodstream, making immediate cessation of use non-negotiable for anyone who has not yet administered the product. Do not attempt to filter or inspect the vial visually to see if it looks clear; particulate matter can be microscopic or hidden within the liquid, and visual inspection is not a reliable safety check for this type of contamination. The next step involves taking inventory. You need to carefully examine your stock of the recalled product to identify the specific lot numbers involved in this FDA Class II recall. As outlined in the official notice, only products with Lot number 25163 and an expiration date of April 30, 2027, are subject to this recall. These items come in two specific packaging configurations: single-dose 1 mL vials (NDC 0517-9302-01) and cartons containing 25 such vials (NDC 0517-9302-25). If your inventory includes any of these exact lot numbers, you are holding the affected units. It is important to double-check that you do not have other lots or expiration dates, as those products are not part of this specific safety alert and can be used normally if they meet all other storage and handling guidelines. Once you have confirmed possession of the recalled items, you must contact American Regent, Inc., the manufacturer based in Shirley, New York, to initiate the return process. The official recall announcement does not explicitly detail a pre-paid shipping label or a specific digital portal for consumers to upload proof of purchase. Therefore, you should call their customer service or medical affairs department directly to report your possession of Lot 25163 and request instructions on how to return the product. They will guide you through their specific logistics for retrieving the contaminated vials from your facility or home. Do not dispose of the product in regular household trash or via standard pharmaceutical take-back programs without explicit instruction, as improper disposal could expose others to the hazardous particulates mentioned in the hazard description. While waiting for return instructions, store the recalled Multrys securely away from any patients or individuals who might accidentally use them. Keep the original packaging intact if possible, as it contains the lot number and NDC information that American Regent will need to process your case efficiently. If you are a healthcare professional, document the quantity of recalled units in your inventory management system and flag them clearly as "DO NOT USE" to prevent any accidental administration during this interim period. Your cooperation is vital in helping the FDA and the manufacturer remove these unsafe products from the supply chain completely.Your refund, repair, or replacement options
When a medical product is recalled, the most immediate concern for patients and healthcare providers is often the logistical question of what happens next with the physical item. In this specific instance involving American Regent, Inc.’s recall of Multrys (Trace Elements Injection 4, USP), the official recall announcement from the FDA does not explicitly state a standardized remedy such as a direct refund, a replacement shipment, or a repair service in the public record provided. This absence of explicit remediation details in the initial filing is not uncommon for Class II recalls involving pharmaceutical contaminants, particularly when the issue relates to manufacturing anomalies like particulate matter rather than a fundamental formulation error. However, the lack of a pre-written "refund policy" in the recall notice does not mean you are left without recourse. It simply means that the process requires proactive communication with the manufacturer or your healthcare provider to navigate.
The primary path for resolving this issue lies in direct contact with American Regent, Inc., the company responsible for manufacturing and distributing these products. Since the recall is nationwide and involves specific lots (Lot #25163) distributed from their facility in Shirley, New York, they are the entity obligated to manage the return or destruction of the contaminated stock. If you are a healthcare facility that has not yet administered the drug, you should contact American Regent’s customer service or quality assurance department immediately. They will typically provide instructions on how to return the vials for proper disposal or offer a credit against future orders, though these specific financial terms are not detailed in the current recall data. For individual patients, this conversation usually happens through your pharmacy or hospital discharge planner, who acts as the intermediary between you and the manufacturer.
If you have already received or used the product, the concept of a "refund" shifts from a simple transactional return to a matter of medical oversight. Because the hazard involves particulate matter such as hair, glass, or paraformaldehyde, the risk is not just about the efficacy of the trace elements but about potential physical harm if injected. Therefore, your immediate "option" is to ensure that any remaining vials are kept in a secure location and not used under any circumstances. You should report any adverse events or concerns directly to the FDA’s MedWatch program and to American Regent. While the recall notice does not promise automatic financial compensation for medical expenses incurred due to the defect, manufacturers often have internal patient assistance or liability processes that can be accessed through their legal or customer relations departments. It is crucial to keep all packaging, lot numbers, and purchase receipts as evidence.
For those who are anxious about the cost of replacing necessary trace elements, it is important to remember that this recall is specific to Lot #25163 with an expiration date of April 30, 2027. Other lots from American Regent or similar products from different manufacturers may still be safe and available. Your healthcare provider can help you determine if alternative sources are appropriate for your treatment plan. The goal here is not just financial restitution but ensuring that your medical care continues without interruption while the contaminated supply chain is cleaned up. Do not hesitate to ask your pharmacy to verify if they have received specific instructions from American Regent regarding credits or replacements, as these operational details can sometimes be communicated directly to distributors before they appear in public federal databases.
What can happen if you ignore it
When a medical product is recalled due to the presence of particulate matter, the stakes are significantly higher than with many other types of consumer goods. In this specific case involving American Regent’s Multrys (Trace Elements Injection 4, USP), the contamination involves hair, glass, and/or paraformaldehyde. Ignoring a recall for an intravenous (IV) product is not merely a matter of inconvenience; it is a direct threat to physical safety because the medication bypasses the body’s natural filtration systems. When you take a pill, your digestive system acts as a barrier. When a drug is injected directly into the bloodstream, that protection disappears entirely. Any foreign object introduced at this stage can travel immediately to vital organs, creating risks that are both immediate and potentially long-term. The most urgent danger comes from the physical nature of the contaminants. Glass shards, for instance, are sharp and rigid. If these particles enter a vein, they can cause mechanical damage to the delicate lining of blood vessels or, more critically, lodge in small capillaries within the lungs, heart, or brain. This can lead to embolisms, which block blood flow and deprive tissues of oxygen. Hair fibers, while softer, are not sterile in the context of an IV line and can introduce bacteria deep into the circulatory system, leading to severe infections like sepsis. Sepsis is a life-threatening response to infection that can cause tissue damage, organ failure, and death if not treated aggressively and immediately. Beyond the physical blockages and infectious risks, there is the chemical hazard posed by paraformaldehyde. This substance is often used in manufacturing processes as a preservative or sterilizing agent, but it is not intended for human injection. Paraformaldehyde can break down into formaldehyde gas within the body, which is a known irritant and toxin. Exposure to formaldehyde through intravenous administration can cause severe inflammatory reactions, allergic responses, and toxicity that damages cells and tissues. The symptoms might not always be instant; they can develop over hours or days as the body struggles to process these foreign substances, leading to confusion, fever, difficulty breathing, or pain at the injection site that worsens rather than improves. Furthermore, using contaminated trace elements means you are not receiving the nutritional support your body needs for recovery or maintenance. Instead, you are introducing a compromised product that may alter the pH balance or osmolarity of the solution, potentially causing additional stress to your kidneys and liver as they try to filter out these toxins. The combination of physical trauma, chemical toxicity, and infection risk creates a compounding effect that is far more dangerous than any single issue alone. Continuing to use this product ignores the FDA’s Class II classification, which indicates that use could cause temporary medical problems or threaten serious injury. By proceeding despite the recall, you are gambling with your vascular health and overall systemic stability, risking outcomes that could require emergency hospitalization, prolonged treatment, or permanent damage. The potential cost of ignoring this warning is measured in health complications that are far more difficult and expensive to treat than simply returning a recalled vial.Staying safe: broader tips
While this specific recall highlights a serious manufacturing issue regarding particulate contamination in intravenous medications, it serves as a powerful reminder that safety in healthcare often depends on rigorous oversight and vigilant personal habits. When dealing with prescription drugs, particularly those administered via injection or infusion, the margin for error is incredibly small. The presence of foreign objects like hair or glass in a sterile product is not just a quality control failure; it is a direct threat to vascular health. For patients and caregivers who rely on such medications at home or in clinical settings, understanding how to proactively protect yourself goes beyond simply checking lot numbers. It involves building a system of verification and environmental awareness that catches issues before they become emergencies.
First, always maintain a dedicated record of your medication inventory. Keep all packaging, boxes, and documentation from your pharmacy or hospital supply room in a safe, easily accessible place until you have completed the full course of treatment. Many people discard these items immediately, but they are your only proof of identity for the product. If you ever notice any irregularities—such as cloudy fluid, unexpected discoloration, or visible particles when you hold the vial up to the light against a white background—do not use it. It is far better to call your healthcare provider or pharmacist with a suspicious-looking item than to risk an infusion. Trust your eyes; if something looks wrong, it almost certainly is.
Furthermore, stay connected with official government resources without waiting for a crisis to prompt you. The U.S. Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS) regularly issue safety communications that are often overlooked by the general public but are critical for patient safety. Consider subscribing to email alerts from the FDA’s Safety Recall page or using their mobile app, which can push notifications directly to your device. This proactive approach ensures that you are among the first to know if a widely used medication is pulled from shelves. Additionally, never hesitate to ask your healthcare provider about the manufacturer and lot number of any new prescription. It is a normal part of the medical process, and it empowers you to cross-reference the information with public recall databases independently.
Finally, advocate for clear communication within your care team. If you are receiving home infusion therapy, ensure that your nursing staff or pharmacy partner has a robust protocol for checking recalls before every delivery. Ask them specifically: "Have you checked for any current FDA alerts regarding this manufacturer or lot number?" This creates a double-check system that adds a layer of security. By combining personal vigilance with official monitoring and open dialogue with your medical providers, you transform passive consumption of healthcare into active management of your own safety. These habits protect you not only from recalled products but also from broader issues like counterfeit drugs or storage-related degradation, ensuring that the care you receive is as safe as it is effective.